Interpublic Group chairman and chief executive told Advertising Week Europe how he managed to turn an "all white, all male" company into one with 54% female leadership.
Want to get an ethicist agitated? Mention the integration of voice-activation and other tech into healthcare. Experts say navigating this area is a work in progress.
The general sense: Nobody should get comfortable with the status quo
MM&M has announced its annual showcase of executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.
Roche's immunotherapy Tecentriq, when combined with a Abraxane-based chemo, decreased the risk of disease worsening or death compared to chemo alone in first-line patients with advanced squamous non-small cell lung cancer; President Trump spoke about using federal prosecutors to sue opioid makers; Trump also vowed to bring down the cost of prescription drugs.
Congress has spent less than a quarter of the $500 million to fight the opioid epidemic; The #MeToo movement is gaining steam in the medical industry; Dr. Robert R. Redfield, a leading AIDS researcher, is the top candidate to lead the Centers for Disease Control and Prevention.
Pfizer persuades Read to stay another year; House GOP to take another crack at "right to try"; Lundbeck plans to acquire Prexton Therapeutics.
How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
FDA moves to limit nicotine in cigarettes; Alexion reports positive test for rare blood disorder treatment; Oregon governor signs drug pricing transparency bill.
MM&M spoke with Gazzaley about what's next for Akili, how he defines "digital medicine," and where the field is currently positioned on the hype cycle.
Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.
As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.
UnitedHealth names Witty as Optum CEO; Gilead R&D chief to exit; Novartis ups chief digital officer to executive committee.
Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.
Health's popularity at SXSW continues to build. Here's our opening weekend wrap-up.
Regeneron, Sanofi cut cost of Praluent for wider coverage; GSK to maintain Advair exclusivity for 2018; 'Right to try' bill introduced in House.
White House quashes Idaho's insurance plans; Voyager reports positive results in clinical trial for Parkinson's drug; Cigna-Express Scripts deal to face long review.
Now more than ever, patients aren't shy about sharing their wants and needs. Here, 8,000 patients from three generations in the U.S., U.K., Germany, and France weigh in on everything from brand loyalty to the factors that drive their decision-making-processes to the reasons they switch treatments.